Literature DB >> 30025681

Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.

Benjamin R Bavinton1, Angie N Pinto2, Nittaya Phanuphak3, Beatriz Grinsztejn4, Garrett P Prestage2, Iryna B Zablotska-Manos5, Fengyi Jin2, Christopher K Fairley6, Richard Moore7, Norman Roth8, Mark Bloch9, Catherine Pell10, Anna M McNulty11, David Baker12, Jennifer Hoy13, Ban Kiem Tee14, David J Templeton15, David A Cooper16, Sean Emery17, Anthony Kelleher2, Andrew E Grulich2.   

Abstract

BACKGROUND: Evidence on viral load and HIV transmission risk in HIV-serodiscordant male homosexual couples is limited to one published study. We calculated transmission rates in couples reporting condomless anal intercourse (CLAI), when HIV-positive partners were virally suppressed, and daily pre-exposure prophylaxis (PrEP) was not used by HIV-negative partners.
METHODS: In the Opposites Attract observational cohort study, serodiscordant male homosexual couples were recruited from 13 clinics in Australia, one in Brazil, and one in Thailand. At study visits, HIV-negative partners provided information on sexual behaviour and were tested for HIV and sexually transmitted infections; HIV-positive partners had HIV viral load tests, CD4 cell count, and sexually transmitted infection tests done. Viral suppression was defined as less than 200 copies per mL. Linked within-couple HIV transmissions were identified with phylogenetic analysis. Incidence was calculated per couple-year of follow-up, focusing on periods with CLAI, no use of daily PrEP, and viral suppression. One-sided upper 95% CI limits for HIV transmission rates were calculated with exact Poisson methods.
FINDINGS: From May 8, 2012, to March 31, 2016, in Australia, and May 7, 2014, to March 31, 2016, in Brazil and Thailand, 358 couples were enrolled. 343 couples had at least one follow-up visit and were followed up for 588·4 couple-years. 258 (75%) of 343 HIV-positive partners had viral loads consistently less than 200 copies per mL and 115 (34%) of 343 HIV-negative partners used daily PrEP during follow-up. 253 (74%) of 343 couples reported within-couple CLAI during follow-up, with a total of 16 800 CLAI acts. Three new HIV infections occurred but none were phylogenetically linked. There were 232·2 couple-years of follow-up and 12 447 CLAI acts in periods when CLAI was reported, HIV-positive partners were virally suppressed, and HIV-negative partners did not use daily PrEP, resulting in an upper CI limit of 1·59 per 100 couple-years of follow-up for transmission rate.
INTERPRETATION: HIV treatment as prevention is effective in men who have sex with men. Increasing HIV testing and linking to immediate treatment is an important strategy in HIV prevention in homosexual men. FUNDING: National Health and Medical Research Council; amfAR, The Foundation for AIDS Research; ViiV Healthcare; and Gilead Sciences.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30025681     DOI: 10.1016/S2352-3018(18)30132-2

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  116 in total

1.  The Unanticipated Benefits of PrEP for Young Black Gay, Bisexual, and Other Men Who Have Sex with Men.

Authors:  Katherine G Quinn; Erika Christenson; Mark T Sawkin; Elizabeth Hacker; Jennifer L Walsh
Journal:  AIDS Behav       Date:  2020-05

2.  Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models.

Authors:  Jennifer A Juno; Kathleen M Wragg; Anne B Kristensen; Wen Shi Lee; Kevin J Selva; Renee M van der Sluis; Anthony D Kelleher; Benjamin R Bavinton; Andrew E Grulich; Sharon R Lewin; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 3.  Interventions to improve the HIV continuum of care in China.

Authors:  Xiangjun Zhang; Na Wang; Sten H Vermund; Huachun Zou; Xianhong Li; Fujie Zhang; Han-Zhu Qian
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

4.  HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers.

Authors:  Steven A John; Katherine G Quinn; Benedikt Pleuhs; Jennifer L Walsh; Andrew E Petroll
Journal:  AIDS Behav       Date:  2020-11

5.  The Time Is Now to End the HIV Epidemic.

Authors:  Brett P Giroir
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

6.  Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits.

Authors:  Robert W Eisinger; Gregory K Folkers; Anthony S Fauci
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

7.  Defining Sexual Risk in the Era of Biomedical HIV Prevention: Implications for HIV Research and Practice.

Authors:  Keith J Horvath; Sara Lammert; Aldona Martinka; Darin Erickson
Journal:  Arch Sex Behav       Date:  2019-10-19

8.  PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples.

Authors:  Hannah N Gilbert; Monique A Wyatt; Emily E Pisarski; Timothy R Muwonge; Renee Heffron; Elly T Katabira; Connie L Celum; Jared M Baeten; Jessica E Haberer; Norma C Ware
Journal:  J Acquir Immune Defic Syndr       Date:  2019-11-01       Impact factor: 3.731

9.  Stages of Adoption of "Treatment as Prevention" Among HIV-Negative Men Who Have Sex with Men Who Engage in Exchange Sex.

Authors:  Étienne Meunier; Karolynn Siegel; Anne E Sundelson; Eric W Schrimshaw
Journal:  AIDS Patient Care STDS       Date:  2020-09       Impact factor: 5.078

10.  Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review.

Authors:  Jennifer LeMessurier; Gregory Traversy; Olivia Varsaneux; Makenzie Weekes; Marc T Avey; Oscar Niragira; Robert Gervais; Gordon Guyatt; Rachel Rodin
Journal:  CMAJ       Date:  2018-11-19       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.